<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is the leading cause of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> and a major cause of cardiovascular mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> has been categorized into stages: <z:mp ids='MP_0002959'>microalbuminuria</z:mp> and macroalbuminuria </plain></SENT>
<SENT sid="2" pm="."><plain>The cut-off values of micro- and macroalbuminuria are arbitrary and their values have been questioned </plain></SENT>
<SENT sid="3" pm="."><plain>Subjects in the upper-<z:mpath ids='MPATH_458'>normal</z:mpath> range of <z:mp ids='MP_0002871'>albuminuria</z:mp> seem to be at high risk of progression to micro- or macroalbuminuria and they also had a higher blood pressure than normoalbuminuric subjects in the lower normoalbuminuria range </plain></SENT>
<SENT sid="4" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> screening is made by measuring albumin in spot urine </plain></SENT>
<SENT sid="5" pm="."><plain>If abnormal, it should be confirmed in two out three samples collected in a three to six-months interval </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, it is recommended that glomerular filtration rate be routinely estimated for appropriate screening of <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, because some patients present a decreased glomerular filtration rate when urine albumin values are in the <z:mpath ids='MPATH_458'>normal</z:mpath> range </plain></SENT>
<SENT sid="7" pm="."><plain>The two main risk factors for diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> are <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo>, but the genetic susceptibility in both type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is of great importance </plain></SENT>
<SENT sid="8" pm="."><plain>Other risk factors are smoking, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, glomerular hyperfiltration and dietary factors </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000112'>Nephropathy</z:hpo> is pathologically characterized in individuals with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> by thickening of glomerular and tubular basal membranes, with progressive mesangial expansion (diffuse or nodular) leading to progressive reduction of glomerular filtration surface </plain></SENT>
<SENT sid="10" pm="."><plain>Concurrent interstitial morphological alterations and hyalinization of afferent and efferent glomerular arterioles also occur </plain></SENT>
<SENT sid="11" pm="."><plain>Podocytes abnormalities also appear to be involved in the <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo> process </plain></SENT>
<SENT sid="12" pm="."><plain>In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, renal lesions are <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> and more complex than in individuals with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>Treatment of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is based on a multiple risk factor approach, and the goal is retarding the development or progression of the disease and to decrease the subject's increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Achieving the best metabolic control, treating <z:hpo ids='HP_0000822'>hypertension</z:hpo> (&lt;130/80 mmHg) and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> (<z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> &lt;100 mg/dl), using drugs that block the renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system, are effective strategies for preventing the development of <z:mp ids='MP_0002959'>microalbuminuria</z:mp>, delaying the progression to more advanced stages of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and reducing cardiovascular mortality in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>